On April 18, 2017, representatives of the Company informed Mr. Durden that the Company intended to terminate the Barrington Consulting Agreement, effective immediately. Neither Mr. Durden nor Barrington Advisory Group LLC intends to enter into any consulting arrangements with the Company following Mr. Durden’s election to the Board or during Mr. Durden’s service on the Board.
On April 18, 2017, the Board met and determined that Mr. Rosenthal would not be included in its slate of candidates nominated for election at the Annual Meeting. Further, at this meeting, the Board also determined that it no longer deemed Mr. Rosenthal as an independent director for purposes of the NASDAQ listing standards and, accordingly, Mr. Rosenthal was removed from the Audit, Compensation and Governance and Nominating Committees of the Board.
On April 19, 2017, the Company filed a preliminary Consent Revocation Statement with the SEC.
On April 20, 2017, the Company delivered a letter to Mr. Baksa expressing its concerns that the Nominating Notice may not comply with the March Amended Bylaws and requesting verification and confirmation of certain information contained in the Nominating Notice.
On April 21, 2017, Mr. Baksa filed Amendment No. 1 to the Preliminary Consent Solicitation Statement with the SEC.
On April 21, 2017, the Executive Committee of the Board designated the close of business on Monday, May 1, 2017, as the record date for the determination of the stockholders of record of outstanding shares that are entitled to execute, withhold or revoke consents with respect to the Consent Solicitation.
On April 25, 2017, the Company issued a press release to announce the promotion of Jon Lowen, Executive Vice President of Operations and Product Development, to Chief Operating Officer of the Company.
On April 25, 2017, the Company issued a press release wherein it commented on Amendment No. 1 to the Preliminary Consent Solicitation Statement filed with the SEC by Mr. Baksa on April 21, 2017 and urged the Company’s stockholders to refrain from taking any action with respect to the Consent Solicitation at that time.
On April 26, 2017, Mr. Baksa filed Amendment No. 2 to the Preliminary Consent Solicitation Statement with the SEC.
On April 27, 2017, Mr. Baksa filed Amendment No. 3 to the Preliminary Consent Solicitation Statement with the SEC.
On April 28, 2017, the Company filed a revised preliminary Consent Revocation Statement with the SEC, alleging, among other things, that the Consent Solicitation was motivated by a desire of Mr. Baksa “to advance an undisclosed agenda related to Evolving Systems, Inc.”
On April 28, 2017, Messrs. Baksa and Candelaria, transmitted a letter to the Corporate Secretary of the Company (the “April 28 Letter”), in response to the Company’s request dated April 20, 2017, pursuant to which, in accordance with the March Amended Bylaws, Messrs. Baksa and Candelaria confirmed and verified that the information in the Nomination Notice was accurate and true, and did not contain any false and misleading statements or other statements that may violate the Exchange Act or other applicable law, in accordance with Section 2(a)(2) of the Company’s Bylaws. The April 28 Letter confirmed and verified the information in the Nomination Notice as required by the Company’s March Amended Bylaws. In addition, the April 28 Letter stated, among other things, the view of Messrs. Baksa and Candelaria that the Company’s request “reflects a poorly-camouflaged attempt by the current Board to impose yet another impediment to the fundamental and intrinsic right of shareholders to nominate candidates of their choosing to serve on the Board, and far exceeds the Company’s authority under . . . the Bylaws” and “clearly represents an unreasonable abuse of discretion by the current Board and is inimical to both fundamental principles of corporate democracy and the will of the Company’s shareholders.”
The April 28 Letter also expressed concern “that the current directors are prolonging the review of the Nomination Notice unnecessarily to entrench themselves and frustrate and disenfranchise the shareholders of the Company.” As such, the April 28 Letter urged the Governance and Nominating Committee of the